Apremilast

USDailyMed:Apremilast AU:B3 L04AA32(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide 608141-41-9 11561674 DB05676 9736448 UP7QBP99PN D08860 CHEBI:78540 ChEMBL514800 DTXSID30976289 Interactive image O=S(=O)(C)C[C@H](c1ccc(OC)c(OCC)c1)N3C(=O)c2cccc(c2C3=O)NC(=O)C InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1Key:IMOZEMNVLZVGJZ-QGZVFWFLSA-N Apremilast, sold under the brand nameOtezlaamong others, is a medication for the treatment of certain types ofpsoriasisandpsoriatic arthritis.The drug acts as a selective inhibitor of the enzymephosphodiesterase 4(PDE4).It is takenby mouth.